NCT02171455已完成1 期
Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of 600 mg, 750 mg and 900 mg Dabigatran Etexilate as Capsule in Healthy Subjects. A Randomised, Placebo-controlled Study, Double Blind at Each Dose Level
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- Frequency [N (%)] of subjects with adverse events
研究概览
简要总结
To assess safety, pharmacokinetics and the effect of dabigatran on coagulation parameters prior to administration of a high dose of dabigatran etexilate in a QT study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- •Age ≥18 and ≤55 years
- •Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.
排除标准
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Relevant surgery of gastrointestinal tract
- •History of any bleeding disorder or acute blood coagulation defect
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Alcohol abuse (more than 60 g/day)
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
研究组 & 干预措施
Dabigatran etexilate low dose
Experimental
干预措施: Dabigatran etexilate low dose (Drug)
Dabigatran etexilate low dose
Experimental
干预措施: Placebo (Drug)
Dabigatran etexilate medium dose
Experimental
干预措施: Dabigatran etexilate medium dose (Drug)
Dabigatran etexilate medium dose
Experimental
干预措施: Placebo (Drug)
Dabigatran etexilate high dose
Experimental
干预措施: Dabigatran etexilate high dose (Drug)
Dabigatran etexilate high dose
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Frequency [N (%)] of subjects with adverse events
时间窗: up to 18 days
次要结局
- Cmax (maximum measured concentration of free and total BIBR 953 ZW in plasma)(up to 72 hours after administration)
- tmax (time from dosing to maximum measured concentration)(up to 72 hours after administration)
- AUC0-∞ (area under the concentration-time curve of free and total BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity)(up to 72 hours after administration)
- λz (terminal rate constant in plasma)(up to 72 hours after administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 72 hours after administration)
- MRTpo (mean residence time of the analyte in the body after oral administration)(up to 72 hours after administration)
- CL/F (apparent clearance of the analyte in plasma after extravascular administration)(up to 72 hours after administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 72 hours after administration)
- Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)(up to 72 hours after administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(up to 72 hours after administration)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(up to 72 hours after administration)
研究者
相似试验
已完成
不适用
Effect of Dabigatran on Coagulation parameters-an ex Vivo StudyEffect of Dabigatran in Laboratory Coagulation ParametersNCT01112202Johann Wolfgang Goethe University Hospital70
已完成
不适用
A Prospective Pharmacodynamic Study of DabigatranBlood Coagulation TestsNCT01588327University of North Carolina, Chapel Hill65
Unknown
4 期
Dabigatran in Patients With Atrial Fibrillation and Mitral Biological ProsthesesMitral Valve Stenosis and InsufficiencyAtrial FibrillationNCT03183843Research Institute for Complex Problems of Cardiovascular Diseases, Russia40
已完成
1 期
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male SubjectsHealthyNCT02171468Boehringer Ingelheim48
撤回
不适用
Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin TherapyVenous ThrombosesNCT01810237Nova Scotia Health Authority